CANCER IMMUNOTHERAPY OF PANCREATIC ADENOCARCINOMA: EFFICACY, LIMITATIONS, AND SIDE EFFECTS

Radka Lencová1, Andrea Frejlachová1, Jan Ženka1

1 Department of Medical Biology, Faculty of Science, University of South Bohemia, České Budějovice, Czech Republic

Cancer remains an unsolved problem of current medicine, and its incidence rises every year [1]. The way to solve this problem could be cancer immunotherapy. Although the first attempts at modern history are attributed to doctor William Coley in 1893 [2], this therapeutic approach has not been fully developed until the last few decades. It could replace or supplement ineffective and dangerous chemotherapy and radiotherapy.

Tumour cells are mutated cells that have escaped the immune system's attention, usually eliminating such damaged cells. Tumour cells can effectively defend themselves against the cells of the immune system, are invisible to them, or the specific tumour microenvironment does not allow immune cells to enter the tumour. For immunotherapy to be successful, these mechanisms must be broken or bypassed [3].

To solve this problem, we successfully developed a therapeutical mixture consisting of several components: mannan-BAM (biocompatible anchor for cell membrane with covalently bounded mannan), Toll-like receptors (TLR) agonists R-848, poly (I:C), and lipoteichoic acid (LTA); and agonistic anti-CD40 antibody. This mixture was named MBTA [4, 5].

The primary mechanism of MBTA cancer immunotherapy is based on both innate and adaptive immunity. After the therapeutic mixture is applied directly into the tumour, mannan-BAM is anchored in the cell membrane of the tumour cells. The mannan-binding lectin recognises mannan and triggers the complement cascade via a lectin pathway that ends with the opsonisation of tumour cells by iC3b molecules. Opsonised cancer cells are recognised and killed by innate immune cells whose infiltration into the tumour is promoted by TLR agonists. Anti-CD40 antibody supports the maturation of dendritic cells, which travel to the lymph nodes where they present antigens of killed cancer cells to naïve T cells. Adaptive immunity is involved, establishing immune memory, and activated T lymphocytes travel back to the tumour or metastases and attack them [5].

MBTA immunotherapy is independent of tumour type, including cold tumours with low infiltration by immune cells. We achieved 80% cure of mice bearing advanced pancreatic adenocarcinoma tumours and 100% resistance to re-transplantation [4, 5]. After such positive results, it was decided to move to a more complicated model – a two-tumour pancreatic adenocarcinoma, with one of the tumours simulating a large metastasis. The presence of a second tumour has been found to reduce the effectiveness of MBTA treatment. When MBTA therapeutics were administered into only one of the two tumours, a growth slowdown of the distal tumour was observed. A certain positive effect was also observed when splitting the standard dose of MBTA between the two tumours. However, for better results, it was necessary to double the dose of MBTA, therefore the same amount was applied to each tumour as in the single-tumour models [4].

Nonetheless, increasing the therapeutic dose also increases the risk of side effects. Although the side effects of MBTA are relatively mild than other current therapeutic approaches, we decided to explore them to find ways to avoid them.

Wild-type mice show mild side effects, appearing primarily during the first application of MBTA, and may be attenuated by antihistamines. On the other hand, despite antihistamine administration, mice with genetically blocked adaptive immune cells respond rapidly and die after MBTA application for two or three consecutive days. This situation is avoidable by applying an MBTA with at least five-day gaps.

Due to the high efficacy, we see great potential in MBTA therapeutics in the field of cancer therapy. Therefore, we will continue to investigate its side effects and how to avoid them so that a possible shift from mice to human patients can occur as smoothly as possible.


[1] R. L. Siegel, Cancer Statistics, 2020. CA: A Cancer Journal for Clinicians, 70, 7–30 (2020).

[2] W. B. Coley, The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. The American Journal of the Medical Sciences, 1991(262), 3-11 (1893).

[3] Y. A. Fouad and C. Aanei, Revisiting the hallmarks of cancer. American Journal of Cancer Research, 7(5), 1016–1036 (2017).

[4] O. Uher, V. Caisova, L. Padoukova et al. Mannan-BAM, TLR ligands, and anti-CD40 immunotherapy in established murine pancreatic adenocarcinoma: understanding therapeutic potentials and limitations, 70, 3303-3312 (2021).

[5] O. Uher, V. Caisová, P. Hansen et al., Coley's immunotherapy revived: Innate immunity as a link in priming cancer cells for an attack by adaptive immunity. Seminars in Oncology 46(4-5), 385-392 (2019).